Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.845 |
---|---|
High | 0.863 |
Low | 0.834 |
Bid | -- |
Offer | -- |
Previous close | 0.846 |
Average volume | 11.37k |
---|---|
Shares outstanding | 25.21m |
Free float | 25.14m |
P/E (TTM) | -- |
Market cap | 22.65m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:40 GMT.
More ▼
Announcements
- Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
- Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
- Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
- Tempest Extends Limited Duration Stockholder Rights Plan
- Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
- Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
- Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
More ▼